Prelude Therapeutics (PRLD) Profit After Tax (2019 - 2026)
Prelude Therapeutics (PRLD) reported Profit After Tax of -$10.4 million for Q1 2026, up 67.5% on a YoY basis from -$6.2 million in Q1 2025, and up 36.47% sequentially from -$16.4 million in Q4 2025.
Prelude Therapeutics (PRLD) Profit After Tax (2019 - 2026) Analysis & Trends
Prelude Therapeutics (PRLD) has 8 years of Profit After Tax data on file, last reported at -$10.4 million in Q1 2026.
- For the quarter ending Q1 2026, Profit After Tax rose 67.5% year-over-year to -$10.4 million; the trailing twelve-month figure through Mar 2026 stood at -$77.8 million (up 39.23% YoY), and the FY2025 full-year result was -$99.5 million, up 21.88% from the prior year.
- Profit After Tax rose to -$10.4 million in Q1 2026, from -$16.4 million in the prior quarter.
- In the past five years, Profit After Tax ranged from a high of -$10.4 million in Q1 2026 to a low of -$34.7 million in Q2 2024.
- A 5-year average of -$27.8 million and a median of -$30.0 million in 2022 frame the typical range for Profit After Tax.
- Across the five-year window, Profit After Tax tumbled 38.33% in 2022 and jumped 67.5% in 2026, its largest moves.
- Tracing PRLD's Profit After Tax over 5 years: stood at -$28.0 million in 2022, then dropped by 15.29% to -$32.2 million in 2023, then grew by 10.32% to -$28.9 million in 2024, then soared by 43.21% to -$16.4 million in 2025, then jumped by 36.47% to -$10.4 million in 2026.
- Business Quant data shows PRLD's Profit After Tax at -$10.4 million in Q1 2026, -$16.4 million in Q4 2025, and -$19.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -36.84 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -65.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Prelude Therapeutics | 324.30 Mn | 179.71 Mn | - | -10.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -10.43 Mn |
| Dec 31, 2025 | -16.42 Mn |
| Sep 30, 2025 | -19.73 Mn |
| Jun 30, 2025 | -31.23 Mn |
| Mar 31, 2025 | -32.11 Mn |
| Dec 31, 2024 | -28.92 Mn |
| Sep 30, 2024 | -32.27 Mn |
| Jun 30, 2024 | -34.74 Mn |
| Mar 31, 2024 | -31.43 Mn |
| Dec 31, 2023 | -32.25 Mn |
| Sep 30, 2023 | -30.61 Mn |
| Jun 30, 2023 | -30.43 Mn |
| Mar 31, 2023 | -27.72 Mn |
| Dec 31, 2022 | -27.97 Mn |
| Sep 30, 2022 | -30.03 Mn |
| Jun 30, 2022 | -27.37 Mn |
| Mar 31, 2022 | -29.47 Mn |
| Dec 31, 2021 | -32.84 Mn |
| Sep 30, 2021 | -30.86 Mn |
| Jun 30, 2021 | -26.87 Mn |